ReviewFrontiers in pharmacology2025
Research progress of quercetin on anti-anxiety and anti-depression.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bioactive Oil Blend Nanoemulsion Attenuates Depression-like Behavior Through Modulation of Neuroimmune-Related Inflammatory Pathways in Experimental Rheumatoid Arthritis.Life (Basel, Switzerland) · 2026Article
- The crosstalk between nerves and immunity: chronic stress as a driver of tumor progression.Frontiers in immunology · 2026Review
- Zuo Gui Wan Promotes Remyelination in Multiple Sclerosis by Attenuating MAPK-Mediated Microglial M1 Polarization, an Integrated Network Pharmacology and Experimental Validation Study.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety and depression represent two of the most prevalent mental disorders worldwide, with current pharmacotherapies often limited by adverse effects and treatment resistance. Consequently, research into natural products for mental health interventions has attracted growing scientific interest. Quercetin, a bioactive flavonoid ubiquitously present in plant-derived flowers, fruits, and dietary sources, exhibits diverse pharmacological properties, including antioxidant, anxiolytic, and antidepressant activities. This review systematically summarizes the fundamental characteristics of quercetin, focusing on its core molecular mechanisms in alleviating anxiety- and depression-like behaviors, preclinical evidence from experimental models, and the current landscape of clinical investigations. By critically analyzing its therapeutic advantages, translational challenges, and emerging research priorities, this synthesis aims to offer a theoretical foundation for the development of quercetin-based formulations and their clinical implementation in mood disorder management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.